KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Financing Activities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Cash from Financing Activities data on record, last reported at -$77.2 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 80.27% year-over-year to -$77.2 million; the TTM value through Dec 2025 reached -$2.3 billion, down 51.27%, while the annual FY2025 figure was -$2.3 billion, 51.27% down from the prior year.
  • Cash from Financing Activities reached -$77.2 million in Q4 2025 per VRTX's latest filing, up from -$1.2 billion in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $47.7 million in Q2 2022 and bottomed at -$1.2 billion in Q3 2025.
  • Average Cash from Financing Activities over 5 years is -$293.2 million, with a median of -$315.4 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: soared 111.96% in 2022, then plummeted 2172.83% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$336.2 million in 2021, then surged by 111.96% to $40.2 million in 2022, then plummeted by 398.01% to -$119.8 million in 2023, then tumbled by 226.63% to -$391.3 million in 2024, then skyrocketed by 80.27% to -$77.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$77.2 million in Q4 2025, -$1.2 billion in Q3 2025, and -$349.2 million in Q2 2025.